Could a cancer pill keep lung cancer in check? new trial investigates
NCT ID NCT02679963
First seen Apr 09, 2026 · Last updated May 24, 2026 · Updated 8 times
Summary
This study tested whether the drug olaparib could help people with advanced non-small cell lung cancer (NSCLC) who responded to initial chemotherapy. Participants who had a good response to platinum-based chemo were randomly assigned to take either olaparib or a placebo daily to see if it delayed cancer growth. The trial was stopped early, but it aimed to find a new maintenance option for this serious disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Cancer Campus
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.